Taysha Gene Therapies (TSHA) Reports $39.1M Q3 Net Loss; Cash Runway Into 2H 2028

Taysha reported a Q3 2026 net loss of $39.1M, or $0.10 per share, versus $32.7M, or $0.09 per share, a year earlier. It had $422.8M in cash at September 30 and expects resources to support operations into 2H 2028.Material DetailsContext by AI AnalystThis is a mid-cycle update for a clinical-stage c…